NovaBiotics Wins Life Science Business Leadership Award
NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company was awarded the Life Science Business Leadership Award at the Scottish Enterprise Life Sciences Annual Dinner on 6 February 2014 at the Edinburgh International Conference Centre.
The Life Science Business Leadership Award is presented to the business leader or management team who has significantly advanced their company in the previous year, with factors such as financing, partnerships, collaborations, achievement of milestones and growth being taken into consideration.
NovaBiotics’ CEO, Dr Deborah O’Neil, won the award for her leadership and vision which has been instrumental in the growth of NovaBiotics. After 11 years of work and 3 years of contract development, Deborah and her team secured an exclusive agreement with Taro Pharmaceuticals to license and co-develop the Company’s lead product Novexatin in August 2013, which is among the largest deals reached in the Scottish life science arena in recent years. NovaBiotics’ unique and ambitious strategy has also been recognised.
Dr O’Neil said: “I am proud of what NovaBiotics has achieved thus far and the Life Science Business Leadership Award reflects this. Our deal with Taro Pharmaceuticals is a huge success for the company and demonstrates industry confidence in our approach. By sticking to our business model and focusing on the results that our research was producing, we have created a solid foundation for our products and vision. Through all of this, we have been very fortunate to have been supported by organisations like the Scottish Enterprise, funding bodies, excellent, sector-specific mentors and a very talented team.”
The awards ceremony, hosted by Scottish Enterprise, recognises the success and achievements of Scotland’s internationally renowned life sciences sector in areas including innovation, investment, community engagement and collaboration. Scottish Enterprise identifies and exploits opportunities for Scotland's economic growth by supporting Scottish companies to compete, helping to build globally competitive sectors, attracting new investment and creating a world-class business environment.
Julia Brown, Director of Life and Chemical Sciences, Scottish Enterprise, said: “Congratulations to Dr O’Neil and to NovaBiotics. This is a fantastic achievement and the company’s continued success, including its international outlook, is very much testament to the innovation, drive and vision that Dr O’Neil demonstrates on a daily basis.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...